A first study has shown promising effects of the EGFR and ERBB2 inhibitor lapatinib on canine TCC cell lines [92], while the EGFR inhibitor erlotinib reduced proliferation in a subset of human TCCs [93, 94]. Here, ERBB2 is linked to tarsal-carpal coalition syndrome.